Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | RBP4 | P02753 | 5/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5997085 | 0.86 | HTR2C (0.41) | HTR2CHTR2BGAATDP1RBP4 | |
| SCHEMBL18754425 | 0.78 | HTR2C (0.41) | HTR2CHTR2BGAATDP1RBP4 | |
| SCHEMBL12924535 | 0.78 | TEAD1 (0.50) | HTR2CHTR2BGAATDP1RBP4 | |
| SCHEMBL5997779 | 0.78 | TP53 (0.39) | HTR2CHTR2BTP53 | |
| SCHEMBL2740658 | 0.78 | HTR2C (0.41) | HTR2CHTR2BGAATDP1RBP4 | |
| SCHEMBL5994321 | 0.73 | TSHR (0.53) | TEAD1 | |
| SCHEMBL5995643 | 0.72 | ALDH1A1 (0.48) | GAATDP1TP53 | |
| SCHEMBL13765305 | 0.71 | NAPRT (0.32) | HTT | |
| SCHEMBL3692855 | 0.70 | HTR2C (0.42) | HTR2CHTR2BGAATDP1RBP4 | |
| SCHEMBL1498947 | 0.69 | HTR2C (0.50) | HTR2CHTR2BGAATDP1RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026321-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1583751-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISEASES | CV THERAPEUTICS, INC. (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20040186109-A1 | piperazine derivatives, e.g., (2R)-1-(2-methylbenzothiazol-5-yloxy)-3-[4-({5-[4-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl)}methyl)piperazinyl]propan-2-ol; treating diabetes, arrhythmia, intermittent claudication, angina, congestive heart disease, and myocardial infarction | CV THERAPEUTICS, INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004069818-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISEASES | CV THERAPEUTICS INC. (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186109-A1 | piperazine derivatives, e.g., (2R)-1-(2-methylbenzothiazol-5-yloxy)-3-[4-({5-[4-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl)}methyl)piperazinyl]propan-2-ol; treating diabetes, arrhythmia, intermittent claudication, angina, congestive heart disease, and myocardial infarction | KCNJ2, PPARA, PPARD | HTR2C 1810/4885HTR2B 3190/4885GAA 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.